Keynote 3 – Martin Cranston King

Strategic applications of risk-based approaches to applying AI in Product Development, Products and Quality Management Systems.

The goal of AI extends beyond mimicking human intelligence to enhancing capabilities that surpass human abilities in specific tasks, ensuring consistency while minimizing human errors. Evaluating and managing risks is essential when integrating any software system including Generative Pre-trained Transformer (GPT) models, Quality Management Systems (QMS), use as a tool in Product Development (Medical Devices & Pharma) or as an integrated part of a Medical Device or Systems.

Join Martin King in this session as he explores the strategic applications of risk-based approaches to applying AI in Product Development, Products and Quality Management Systems.


Martin Cranston King

IT-Juristinnentag 2024 Keynote Speaker 3, Martin King
Martin King

Martin Cranston King is a Swiss consultant with over 30 years of experience in medical devices, in vitro diagnostics (IVD), and pharmaceuticals. His career, which began in 1979, encompasses a focus on quality assurance, regulatory compliance, and product development, including work on active wearable devices since the mid-1980s.

Known for his collaborative approach, high ethical standards, and success in navigating complex regulatory environments, Martin has established himself as a trusted advisor in the medical device and pharmaceutical industries. He has held leadership roles and has successfully guided regulatory submissions on six continents, making him a valued partner for organizations worldwide.

Martin holds a masters-level postgraduate degree in Micro-electronics and Materials Science from Middlesex Polytechnic, London, and Electronic Engineering Diplomas from Southend-on-Sea College of Technology. A trained Lead Auditor for ISO 13485:2016, he has in-depth experience with standards like 21 CFR 820, ISO 14971, and MDR 745/2017.

Identified as one of the top 25 MedTech Leading Voices on LinkedIn, Martin is also known for his weekly regulatory roundup, offering insights into the latest developments in the medical device and IVD sectors.

Scroll to Top